$XBI $73.85 | -6.02%
Table of Contents:
Covid Updates
$
Pipeline Updates
$VTGN -0.7% VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder source
$TPTX -7.3% Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines source
$MBRX -3.9% Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) source
$ARCT -10.6% Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial source
$ALZN -2.8% Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s source
$KMPH -3.1% KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) source
$MRNS -1.1% Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus source
$ICPT +21.0% INTERCEPT ANNOUNCES ADVANZ PHARMA TO ACQUIRE OCALIVA IN PBC IN MARKETS OUTSIDE THE U.S. FOR UP TO $450MM, INCLUDING $405MM UPFRONT AND AN ADDITIONAL $45MM IN CONTINGENT PAYMENTS source
$IMUX -0.4% Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$PLRX -4.8% Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809 source
$AGLE +1.3% Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market source
Posted by JM
Comentários